Table 2 Pathways enriched (FDR < 0.01) by helveticoside
Pattern | KEGG ID | Name | p-value* | FDRa |
|---|---|---|---|---|
Down-regulation | NA | NA | NA | NA |
Up-regulation | hsa4010 | MAPK signaling pathway | 8.00E-07 | 1.10E-04 |
| Â | hsa4350 | TGF-beta signaling pathway | 4.73E-06 | 3.25E-04 |
| Â | hsa4710 | Circadian rhythm | 2.27E-05 | 1.03E-03 |
| Â | hsa4210 | Apoptosis | 7.98E-05 | 2.71E-03 |
| Â | hsa5200 | Pathways in cancer | 8.00E-05 | 2.18E-03 |
| Â | hsa4540 | Gap junction | 8.86E-05 | 2.01E-03 |
| Â | hsa5212 | Pancreatic cancer | 2.05E-04 | 3.96E-03 |
| Â | hsa4060 | Cytokine-cytokine receptor interaction | 2.50E-04 | 4.22E-03 |
| Â | hsa5219 | Bladder cancer | 3.39E-04 | 5.07E-03 |
| Â | hsa4115 | p53 signaling pathway | 4.73E-04 | 6.33E-03 |
| Â | hsa4660 | T cell receptor signaling pathway | 5.15E-04 | 6.27E-03 |
| Â | hsa5221 | Acute myeloid leukemia | 5.31E-04 | 5.94E-03 |
| Â | hsa5211 | Renal cell carcinoma | 5.74E-04 | 5.93E-03 |
| Â | hsa4110 | Cell cycle | 6.00E-04 | 5.76E-03 |
| Â | hsa4621 | NOD-like receptor signaling pathway | 8.03E-04 | 7.15E-03 |
| Â | hsa4662 | B cell receptor signaling pathway | 9.02E-04 | 7.52E-03 |